Everólimus
C53H83NO14
958,24
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone;
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahidro-9,27-dihidroxi-3-[(1R)-2-[(1S,3R,4R)-4-(2-hidroxietoxi)-3-metoxiciclohexil]-1-metiletil]-10,21-dimetoxi-6,8,12,14,20,26-hexametil-23,27-epoxi-3H-pirido[2,1-c][1,4]oxaazaciclohentriacontina-1,5,11,28,29(4H,6H,31H)-pentona [159351-69-6]
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone;
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahidro-9,27-dihidroxi-3-[(1R)-2-[(1S,3R,4R)-4-(2-hidroxietoxi)-3-metoxiciclohexil]-1-metiletil]-10,21-dimetoxi-6,8,12,14,20,26-hexametil-23,27-epoxi-3H-pirido[2,1-c][1,4]oxaazaciclohentriacontina-1,5,11,28,29(4H,6H,31H)-pentona [159351-69-6]
DEFINICIÓN
El Everólimus contiene no menos de 95,0% y no más de 102,0% de everólimus (C53H83NO14), calculado con respecto a la sustancia anhidra y exenta de disolventes. Puede contener un antioxidante adecuado.
ESTÁNDARES DE REFERENCIA USP A LA VENTA
ER Everólimus USPER Mezcla de Aptitud del Sistema de Everólimus USP
ER Sirólimus USP